Analysts and Abivax's CEO believe the upcoming maintenance trial for its drug Obafazimod has a very high probability of success. This confidence is based on the historical rarity of drugs succeeding in the initial 'induction' phase but then failing in the longer 'maintenance' phase for ulcerative colitis.

When a company reports an 'efficacy estimate,' it often excludes patients who dropped out of a trial, inflating perceived success. Investors should demand the 'treatment regimen estimate,' which includes all participants and aligns with what the FDA actually considers for drug approval.

It's a fool's errand to predict specific trial results. A robust quantitative approach to biotech focuses on underlying drivers and base rates. It positions a portfolio so the random, unpredictable nature of trial events plays out favorably over time, guided by factors like valuation and specialist ownership.

Abivax's drug has a novel, not fully understood mechanism (miR-124). However, analysts believe strong clinical data across thousands of patients can trump this ambiguity for doctors and regulators, citing historical precedents like Revlimid for drugs that gained approval despite unclear biological pathways.

Analysts largely overlooked Abivax before its major data success because it was a European company with a recent US listing, its drug was repurposed from an initial indication in HIV, and investor attention in the IBD space was focused on other high-profile mechanisms like TL1A and S1Ps.

Despite a pivotal data readout pending, an acquisition of Abivax could happen beforehand. Historical deals like Merck's acquisition of Prometheus and Pfizer's of Arena show that large pharma companies are willing to 'roll the dice' and pay a premium for pre-data assets when their conviction in the science is high.

Abivax's drug was dismissed by many investors because its mechanism of action was unclear, a common red flag. However, the available clinical data was strong enough to suggest efficacy, meaning the "how" it worked was less important than the evidence "that" it worked for generating alpha.

Contrary to market convention, a trial delay can be a bullish signal. When an independent data monitoring committee (IDMC) recommends adding more patients, as with Bristol's ADEPT-2 study, it implies they've seen a therapeutic signal worth salvaging, potentially increasing the trial's ultimate chance of success.

To be considered a success, Abivax's oral drug Obifazomad must demonstrate placebo-adjusted long-term remission rates of 25-30% in upcoming data, matching the efficacy of top biologic treatments for ulcerative colitis. Its strong phase two results, showing a 48% rate, suggest this benchmark is achievable, positioning it as a potential "holy grail" oral therapy.